Grants for Public and State controlled institutions of higher education - Federal

This funding opportunity supports innovative research projects aimed at advancing prostate cancer prevention, diagnosis, and treatment, specifically targeting high-risk groups such as Service Members and Veterans.

This funding opportunity provides financial support to various organizations to enhance training and technical assistance for health centers, enabling them to improve and integrate behavioral health services for better patient care across the United States.

This funding opportunity supports educational programs that provide research experiences and mentoring to enhance the participation of diverse individuals in the scientific workforce related to hearing and communication disorders.

This grant provides funding for higher education institutions and nonprofit or for-profit organizations to conduct evidence-based seminars that promote American history, civics, and government education in preparation for the nation's 250th anniversary.

This funding opportunity supports innovative research proposals from small businesses, academic institutions, and research organizations to develop high-risk, high-reward microsystem technologies for defense applications.

This funding opportunity supports U.S. colleges and universities in developing innovative curricula on documentary standards and standardization, particularly encouraging participation from community colleges and minority-serving institutions.

This grant provides funding opportunities for research and higher education organizations to collaborate with USAID and local institutions to address key development challenges sustainably.

This funding opportunity supports partnerships among local organizations and governments to strengthen regional food systems and enhance local agricultural economies.

This funding opportunity supports the development of standardized data elements for Alzheimer’s Disease and related dementias research, inviting applications from universities, nonprofits, and other organizations to enhance data sharing and collaboration in the field.

This funding opportunity provides financial support for conservation projects in Mississippi, focusing on outreach, education, and technical assistance to help socially disadvantaged and beginning farmers adopt sustainable agricultural practices.

The Japanese American Confinement Sites Grant Program provides financial assistance to organizations and entities working to preserve historic Japanese American confinement sites and their history, including: private nonprofit organizations; educational institutions; state, local, and tribal governments; and other public entities, for the preservation and interpretation of U.S. confinement sites where Japanese Americans were detained during World War II. The authorizing legislation for the Japanese American Confinement Sites Grant Program identifies up to $38 million for the entire life of the grant program for projects to identify, research, evaluate, interpret, protect, restore, repair, and acquire historic confinement sites in order that present and future generations may learn and gain inspiration from these sites and that these sites will demonstrate the Nations commitment to equal justice under the law (Public Law 109-441, 120 Stat. 3288; as amended by Public Law 111-88). Projects funded through the Japanese American Confinement Sites Grant Program must benefit one or more historic Japanese American confinement sites. The term historic confinement sites is defined as the ten War Relocation Authority sites (Gila River, Granada, Heart Mountain, Jerome, Manzanar, Minidoka, Poston, Rohwer, Topaz, and Tule Lake), as well as other historically significant locations, as determined by the Secretary of the Interior, where Japanese Americans were detained during World War II. These sites are specifically identified in Confinement and Ethnicity: An Overview of World War II Japanese American Relocation Sites, published by the Department of the Interior, National Park Service, Western Archaeological and Conservation Center, in 1999. This document may be seen at www.nps.gov/history/history/online_books/anthropology74 and at other internet sites.

This funding opportunity supports multidisciplinary research centers focused on understanding and improving the transmission of seasonal influenza viruses, inviting applications from a wide range of organizations, including universities, nonprofits, and government entities.

This funding opportunity provides $7.8 million to organizations that improve health, safety, and behavioral outcomes for children and families in Head Start and Early Head Start programs through training and technical assistance.

This funding opportunity provides financial support to various organizations working to strengthen public health systems in Kenya, focusing on preventing and responding to health threats and improving overall health security.

This funding opportunity provides additional financial support for early-stage cancer researchers who have made significant progress in their work, allowing them to extend their research efforts and move towards greater independence in their scientific careers.

This funding opportunity supports educational and mentorship programs that encourage undergraduate and post-baccalaureate students from diverse backgrounds to pursue careers in genomics research.

This funding opportunity announcement (FOA) invites research projects that seek to explain the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in human health, illness, recovery, and overall wellbeing. Types of projects submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical and/or behavioral outcomes in humans to understand fundamental aspects of phenomena related to social connectedness and isolatedness. NIH considers such studies as prospective basic science studies involving human participants that meet the NIH definition of basic research and fall within the NIH definition of clinical trials (see, e.g., NOT-OD-19-024) Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applications proposing studies that include but not limited to model animal research or observational studies involving humans should submit under the companion Clinical Trials Not Allowed version of this FOA.

This grant provides funding for a variety of organizations and individuals to conduct research aimed at understanding and preventing research misconduct, thereby promoting integrity in scientific research.

This funding opportunity supports researchers investigating new and existing risk factors for liver cancer, focusing on population-based studies to improve understanding and prevention of the disease in the U.S.

The purpose of this funding opportunity announcement (FOA) is to solicit applications for pilot projects to elucidate a role for understudied proteins associated with rare diseases. Awards will support generation of preliminary data and/or tools around eligible understudied protein(s).Funding Opportunity Description Introduction The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH), is transforming the translational science process so that new treatments and cures for disease can be delivered to patients faster. NCATS strives to develop innovations to reduce, remove or bypass costly and time-consuming bottlenecks in the translational research pipeline in an effort to speed the delivery of new drugs, diagnostics and medical devices to patients. This funding opportunity announcement (FOA) aims to promote innovative research to increase knowledge of understudied proteins associated with rare diseases. The submission of small research grant (R03) applications is encouraged from institutions and organizations proposing projects leading to a better understanding of eligible proteins listed below. Small research (R03) grants provide flexibility for initiating discrete, well-defined projects that realistically can be completed in one year and require only limited levels of funding. This program supports different types of projects including, but not limited to, the following: Pilot or feasibility studies; Small, self-contained research projects; Development of research methodology; and/or Development of assays to support compound screening projects; Development of human cell or animal based models. These awards will support generation of preliminary data and tools around eligible understudied protein(s) with the intent of elucidating the function of these proteins in the context of rare disease and obtaining sufficient preliminary data and/or research resources for subsequent grant applications and/or drug discovery projects. These grants are non-renewable. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s). Background The human genome has revealed a great deal about the human proteome, though significant portions of the genome remain understudied. Only a subset of expressed proteins demonstrates the requisite properties to serve as targets for the development of therapeutics. Many bona fide drug targets likely remain to be studied in the Druggable Proteome (DP), which can be defined as the fraction of proteins which have the ability to bind drug-like molecules. The term "drug-like" refers to the physical, biochemical, and pharmacological attributes of small molecule compounds that are generally recognized to be required for efficacious clinical drugs in humans. While the number of proteins in the DP is upwards of 4,500, the existing clinical pharmacopeia is represented by only a few hundred targets, leaving a huge swath of druggable biology unexploited. The expanded exploration of the relationship between the protein and the rare disease phenotype, or the development of a useful tool or reagent can accelerate research into a previously understudied protein. Many interesting and critical biological processes and potential therapeutic avenues remain unexplored because an initial catalyzing event (e.g., association with a biologic process or phenotype, creation of tools or reagents for the protein, etc.) has not yet occurred. The purpose of this FOA is to spark such catalyzing events through the support of small R03 awards to identify novel drug targets for the treatment of human disease, specifically rare disease Objectives and Scope The goal of this specific solicitation is to provide a needed opportunity for the collection of preliminary data around the role of understudied proteins associated with rare diseases. This FOA will provide funding to support research that will characterize new targets for treatment of human disease among the understudied proteins of the Druggable Proteome. These projects should be carried out in a short period of time with limited resources as defined by the funding mechanism. It has been recognized through workshops and publications that understudied proteins become illuminated when (1) there are tools to study the protein (e.g., tools that modulate protein activity) and/or (2) there is biochemical, cellular, or animal model evidence of disease/physiological relevance. This FOA was developed to address the need for expanded research and validation experiments on eligible understudied protein(s), with the intent of producing preliminary data to address the lack of biochemical, cellular, or animal model data associated with many understudied proteins. It is expected that the award will be used to obtain preliminary data and/or research resources for subsequent grant applications and/or drug discovery projects. The NIH supports research on a broad range of diseases that are defined as rare; that is diseases affecting fewer than 200,000 individuals in the United States (per the Rare Disease Act of 2002). Collectively, there are an estimated 7,000 rare diseases, which affect approximately 25-30 million people in the United States. Most are serious or life-threatening, with a disproportionate number of rare diseases affecting children. At this time, effective treatments are available for fewer than 5%. The IDG Program has linked over 6,000 proteins to rare diseases, with over 80% of these proteins considered extremely understudied. For the purposes of this FOA, eligible proteins are those that have an association with rare disease through data mining of the encyclopedia of rare disease annotations for precision medicine (eRAM) and Orphanet, are considered understudied (those proteins that lack small molecule binders and/or have limited biological characterization) and are within a protein family that is traditionally considered druggable.